Non-Small-Cell Lung Cancer | China In-Depth | China | 2021

Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, including several targeted and biomarker-driven therapies. Notably, many targeted therapies are intended for patients with activating EGFR mutations, which are more prevalent in China than in the Western markets. We expect China’s NSCLC therapy market to experience robust growth throughout the 2021-2031 forecast period. The key drivers of this market growth will be the continued uptake of targeted and biomarker-driven therapies, including immune checkpoint inhibitors, EGFR inhibitors, and ALK inhibitors. The incorporation of several of these therapies in China’s National Reimbursement Drug List (NRDL) will secure better patient access. Moreover, several targeted therapies are expected to be approved within the forecast period, which will result in increased therapy options and market growth.


  • How large is China’s drug-treatable NSCLC population, and how will drug-treatment rates change during the forecast period?
  • Which are the most commercially relevant drugs in China’s NSCLC market, and why? What are interviewed experts’ insights into current treatment options?
  • What are the market access considerations for key therapies in the NSCLC pipeline in China? What sales could they secure in NSCLC? What are interviewed experts’ opinions of these therapies?
  • What are the key drivers and constraints in the China NSCLC therapy market, and how will the market evolve over the forecast period?


China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.

Release date

March 2022



Primary Research

Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 medical oncologists.


Diagnosed incidence of non-small-cell lung cancer (NSCLC) in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations.


10-year, annualized, drug-level sales and patient share of key NSCLC therapies through 2031, based on primary and secondary market research to formulate bottom-up assumptions.


Phase III/PR: > 20 drugs. Phase II: 20+ drugs. Coverage of select early-phase products.

Login to access report